Shopping Cart 0
Cart Subtotal
AED 0

Kite Pharma Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
AED 918

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
AED 1835

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
AED 2753

Details

Summary

Kite Pharma Inc (Kite Pharma) is a bio-pharmaceutical company that discovers and develops cancer immunotherapy products. The company concentrates on chimeric antigen receptors (CAR) and T cell receptors (TCR) engineered cell therapies. It offers KTE-C19 in a critical trial for the treatment of refractory, aggressive non-Hodgkin Lymphoma (NHL). Kite Pharma also provides early research and product development services. The company developed engineered autologous T-cell therapy (eACT) technology platform that allows to strengthen patient's own immune system to target and kill cancer cells. It works in collaboration with various institutes and companies. The company has operational presence in the Netherlands and the US. Kite Pharma is headquartered in Santa Monica, California, the US.

Kite Pharma Inc-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 6

Kite Pharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7

Kite Pharma Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8

Kite Pharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9

Kite Pharma Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10

Kite Pharma Inc, Medical Devices Deals, 2012 to YTD 2018 11

Kite Pharma Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12

Kite Pharma Inc, Pharmaceuticals & Healthcare, Deal Details 15

Asset Purchase 15

Kite Pharma Acquires Agensys Research Facilities from Astellas Pharma 15

Venture Financing 16

Cell Design Labs Raises USD34.4 Million in Venture Financing 16

Kite Pharma Raises USD 20 Million In Series A Financing 17

Kite Pharma Raises USD 0.2 Million In Venture Financing 18

Partnerships 19

Kite Pharma Enters into Option Agreement with Netherlands Cancer Institute to License T Cell Receptor Cancer Immunotherapy Product Candidates 19

Kite Pharma and Gadeta Enter into Co-Development Agreement 20

Kite Pharma Enters into Partnership with Pfizer 21

Kite Pharma Forms Joint Venture with Fosun Pharma 22

Kite Pharma Enters into Agreement with Vitruvian Networks 23

Kite Pharma Enters into R&D Agreement with National Cancer Institute 24

Kite Pharma Enters into Agreement with Genentech 25

Kite Pharma Enters into Research Agreement with Leiden University Medical Center 26

Kite Pharma Enters into Research and Development Agreement with National Cancer Institute 27

Kite Pharma Enters into Research Agreement with GE Global Research 28

Kite Pharma Enters into Agreement with Leukemia & Lymphoma Society 29

Kite Pharma Enters into Co-Development Agreement with Bluebird bio 30

Adimab Enters into Research Agreement with Kite Pharma 31

Kite Pharma Extends Research Agreement with Tel Aviv Medical Center to Develop Novel Chimeric Antigen Receptor (CAR) 32

Kite Pharma Enters into Research Agreement with Tel Aviv Medical Center 33

Kite Pharma Amends R&D Agreement with National Cancer Institute for Cancer Immunotherapy Products 34

Licensing Agreements 35

Kite Pharma to Enter into Licensing Agreement with Sangamo Therapeutics 35

Daiichi Sankyo Enters into Licensing Agreement with Kite Pharma 37

Kite Pharma Enters into Licensing Agreement with National Institutes of Health 38

Kite Pharma Enters into Licensing Agreement with National Institutes of Health 39

Kite Pharma Enters into Licensing Agreement with Regents of the University of California 40

Kite Pharma Enters into Licensing Agreement with Cell Design Labs 41

Kite Pharma Exercises Option for Licensing Agreement with Adimab 42

Kite Pharma Extends Licensing Agreement with Alpine Immune Sciences 43

Kite Pharma Enters into Licensing Agreement with National Institutes of Health 44

Amgen Enters into Licensing Agreement with Kite Pharma 46

Kite Pharma Enters into Licensing Agreement with National Institutes of Health for T Cell Receptor-Based Products 48

Kite Pharma Enters into Licensing Agreement with Cabaret Biotech 49

Kite Pharma Enters into Licensing Agreement with National Institutes of Health 50

Equity Offering 51

Kite Pharma Raises USD409.7 Million in Public Offering of Shares 51

Kite Pharma Announces Exercise of Over-Allotment Option for Public Offering of Shares for USD37.5 Million 53

Kite Pharma Raises USD28.2 Million Underwriters Exercise of Over-Allotment Option of Public Offering of Shares 55

Kite Pharma Raises USD146.62 Million in IPO 57

Acquisition 59

Gilead Sciences and Kite Pharma Acquire Cell Design Labs 59

Gilead Sciences Acquires Kite Pharma for USD11.9 Billion 60

Kite Pharma Acquires T-Cell Factory 62

Kite Pharma Inc-Key Competitors 63

Kite Pharma Inc-Key Employees 64

Kite Pharma Inc-Locations And Subsidiaries 65

Head Office 65

Other Locations & Subsidiaries 65

Joint Venture 65

Recent Developments 66

Financial Announcements 66

Aug 08, 2017: Kite Reports Second Quarter 2017 Financial Results 66

May 08, 2017: Kite Reports First Quarter Financial Results 68

Feb 28, 2017: Kite Reports Fourth Quarter and Full Year 2016 Financial Results 70

Corporate Communications 72

Jul 09, 2018: Kite Names Michael Amoroso As Senior Vice President And Head Of Worldwide Commercial, Cell Therapy 72

Mar 16, 2017: Kite Announces Appointment of Renowned Cancer Researcher, Owen N. Witte, M.D., to its Board of Directors 73

Jan 05, 2017: Kite Pharma appoints new board member 74

Product News 75

07/20/2017: Kite Highlights Durable Complete Remissions Up to 56+ Months in Patients with Chemorefractory Aggressive Non-Hodgkin Lymphoma (NHL) after Anti-CD19 CAR T-Cell Therapy at the National Cancer Institute 75

06/12/2018: Clinical Data Highlighting Single-Cell Polyfunctionality as a Potential Predictor of Patient Response to CAR-T Cell Therapy Published in Blood 76

Apr 04, 2017: Kite Highlights Publication on Breakthrough in Generating Fully Functioning T Cells from Hematopoietic Precursor Cells by Leading Researchers at the University of California, Los Angeles 77

03/14/2017: Kite Pharma Highlights Publication from the National Cancer Institute Demonstrating Durable Complete Remissions in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma Following Low Dose Conditioning Chemotherapy and Anti-CD19 CAR T-Cell Therapy 78

Product Approvals 79

Jan 03, 2017: Kite Pharma Submits Investigational New Drug (IND) Application for KITE-718, an Investigational Next Generation T-Cell Receptor (TCR) Therapy Targeting Cancer Antigens MAGE A3 and MAGE A6 79

Other Significant Developments 80

Jan 11, 2018: Adimab Initiates Update on Clinical Progression of Partner Programs 80

Appendix 81

Methodology 81

About GlobalData 81

Contact Us 81

Disclaimer 81


List Of Figure

List of Figures

Kite Pharma Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Kite Pharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Kite Pharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Kite Pharma Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Kite Pharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7

Kite Pharma Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 8

Kite Pharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9

Kite Pharma Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10

Kite Pharma Inc, Medical Devices Deals, 2012 to YTD 2018 11


List Of Table

List of Tables

Kite Pharma Inc, Pharmaceuticals & Healthcare, Key Facts, 2016 2

Kite Pharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7

Kite Pharma Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8

Kite Pharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9

Kite Pharma Inc, Deals By Therapy Area, 2012 to YTD 2018 10

Kite Pharma Inc, Medical Devices Deals, 2012 to YTD 2018 11

Kite Pharma Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12

Kite Pharma Acquires Agensys Research Facilities from Astellas Pharma 15

Cell Design Labs Raises USD34.4 Million in Venture Financing 16

Kite Pharma Raises USD 20 Million In Series A Financing 17

Kite Pharma Raises USD 0.2 Million In Venture Financing 18

Kite Pharma Enters into Option Agreement with Netherlands Cancer Institute to License T Cell Receptor Cancer Immunotherapy Product Candidates 19

Kite Pharma and Gadeta Enter into Co-Development Agreement 20

Kite Pharma Enters into Partnership with Pfizer 21

Kite Pharma Forms Joint Venture with Fosun Pharma 22

Kite Pharma Enters into Agreement with Vitruvian Networks 23

Kite Pharma Enters into R&D Agreement with National Cancer Institute 24

Kite Pharma Enters into Agreement with Genentech 25

Kite Pharma Enters into Research Agreement with Leiden University Medical Center 26

Kite Pharma Enters into Research and Development Agreement with National Cancer Institute 27

Kite Pharma Enters into Research Agreement with GE Global Research 28

Kite Pharma Enters into Agreement with Leukemia & Lymphoma Society 29

Kite Pharma Enters into Co-Development Agreement with Bluebird bio 30

Adimab Enters into Research Agreement with Kite Pharma 31

Kite Pharma Extends Research Agreement with Tel Aviv Medical Center to Develop Novel Chimeric Antigen Receptor (CAR) 32

Kite Pharma Enters into Research Agreement with Tel Aviv Medical Center 33

Kite Pharma Amends R&D Agreement with National Cancer Institute for Cancer Immunotherapy Products 34

Kite Pharma to Enter into Licensing Agreement with Sangamo Therapeutics 35

Daiichi Sankyo Enters into Licensing Agreement with Kite Pharma 37

Kite Pharma Enters into Licensing Agreement with National Institutes of Health 38

Kite Pharma Enters into Licensing Agreement with National Institutes of Health 39

Kite Pharma Enters into Licensing Agreement with Regents of the University of California 40

Kite Pharma Enters into Licensing Agreement with Cell Design Labs 41

Kite Pharma Exercises Option for Licensing Agreement with Adimab 42

Kite Pharma Extends Licensing Agreement with Alpine Immune Sciences 43

Kite Pharma Enters into Licensing Agreement with National Institutes of Health 44

Amgen Enters into Licensing Agreement with Kite Pharma 46

Kite Pharma Enters into Licensing Agreement with National Institutes of Health for T Cell Receptor-Based Products 48

Kite Pharma Enters into Licensing Agreement with Cabaret Biotech 49

Kite Pharma Enters into Licensing Agreement with National Institutes of Health 50

Kite Pharma Raises USD409.7 Million in Public Offering of Shares 51

Kite Pharma Announces Exercise of Over-Allotment Option for Public Offering of Shares for USD37.5 Million 53

Kite Pharma Raises USD28.2 Million Underwriters Exercise of Over-Allotment Option of Public Offering of Shares 55

Kite Pharma Raises USD146.62 Million in IPO 57

Gilead Sciences and Kite Pharma Acquire Cell Design Labs 59

Gilead Sciences Acquires Kite Pharma for USD11.9 Billion 60

Kite Pharma Acquires T-Cell Factory 62

Kite Pharma Inc, Key Competitors 63

Kite Pharma Inc, Key Employees 64

Kite Pharma Inc, Subsidiaries 65

Kite Pharma Inc, Joint Venture 65

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

Kite Pharma Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Company Profile

Company Profile Title

Summary

Kite Pharma Inc (Kite Pharma) is a bio-pharmaceutical company that discovers and develops cancer immunotherapy products. The company concentrates on chimeric antigen receptors (CAR) and T cell receptors (TCR) engineered cell therapies. It offers KTE-C19 in a critical trial for the treatment of refractory, aggressive non-Hodgkin Lymphoma (NHL). Kite Pharma also provides early research and product development services. The company developed engineered autologous T-cell therapy (eACT) technology platform that allows to strengthen patient's own immune system to target and kill cancer cells. It works in collaboration with various institutes and companies. The company has operational presence in the Netherlands and the US. Kite Pharma is headquartered in Santa Monica, California, the US.

Kite Pharma Inc-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 6

Kite Pharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7

Kite Pharma Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8

Kite Pharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9

Kite Pharma Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10

Kite Pharma Inc, Medical Devices Deals, 2012 to YTD 2018 11

Kite Pharma Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12

Kite Pharma Inc, Pharmaceuticals & Healthcare, Deal Details 15

Asset Purchase 15

Kite Pharma Acquires Agensys Research Facilities from Astellas Pharma 15

Venture Financing 16

Cell Design Labs Raises USD34.4 Million in Venture Financing 16

Kite Pharma Raises USD 20 Million In Series A Financing 17

Kite Pharma Raises USD 0.2 Million In Venture Financing 18

Partnerships 19

Kite Pharma Enters into Option Agreement with Netherlands Cancer Institute to License T Cell Receptor Cancer Immunotherapy Product Candidates 19

Kite Pharma and Gadeta Enter into Co-Development Agreement 20

Kite Pharma Enters into Partnership with Pfizer 21

Kite Pharma Forms Joint Venture with Fosun Pharma 22

Kite Pharma Enters into Agreement with Vitruvian Networks 23

Kite Pharma Enters into R&D Agreement with National Cancer Institute 24

Kite Pharma Enters into Agreement with Genentech 25

Kite Pharma Enters into Research Agreement with Leiden University Medical Center 26

Kite Pharma Enters into Research and Development Agreement with National Cancer Institute 27

Kite Pharma Enters into Research Agreement with GE Global Research 28

Kite Pharma Enters into Agreement with Leukemia & Lymphoma Society 29

Kite Pharma Enters into Co-Development Agreement with Bluebird bio 30

Adimab Enters into Research Agreement with Kite Pharma 31

Kite Pharma Extends Research Agreement with Tel Aviv Medical Center to Develop Novel Chimeric Antigen Receptor (CAR) 32

Kite Pharma Enters into Research Agreement with Tel Aviv Medical Center 33

Kite Pharma Amends R&D Agreement with National Cancer Institute for Cancer Immunotherapy Products 34

Licensing Agreements 35

Kite Pharma to Enter into Licensing Agreement with Sangamo Therapeutics 35

Daiichi Sankyo Enters into Licensing Agreement with Kite Pharma 37

Kite Pharma Enters into Licensing Agreement with National Institutes of Health 38

Kite Pharma Enters into Licensing Agreement with National Institutes of Health 39

Kite Pharma Enters into Licensing Agreement with Regents of the University of California 40

Kite Pharma Enters into Licensing Agreement with Cell Design Labs 41

Kite Pharma Exercises Option for Licensing Agreement with Adimab 42

Kite Pharma Extends Licensing Agreement with Alpine Immune Sciences 43

Kite Pharma Enters into Licensing Agreement with National Institutes of Health 44

Amgen Enters into Licensing Agreement with Kite Pharma 46

Kite Pharma Enters into Licensing Agreement with National Institutes of Health for T Cell Receptor-Based Products 48

Kite Pharma Enters into Licensing Agreement with Cabaret Biotech 49

Kite Pharma Enters into Licensing Agreement with National Institutes of Health 50

Equity Offering 51

Kite Pharma Raises USD409.7 Million in Public Offering of Shares 51

Kite Pharma Announces Exercise of Over-Allotment Option for Public Offering of Shares for USD37.5 Million 53

Kite Pharma Raises USD28.2 Million Underwriters Exercise of Over-Allotment Option of Public Offering of Shares 55

Kite Pharma Raises USD146.62 Million in IPO 57

Acquisition 59

Gilead Sciences and Kite Pharma Acquire Cell Design Labs 59

Gilead Sciences Acquires Kite Pharma for USD11.9 Billion 60

Kite Pharma Acquires T-Cell Factory 62

Kite Pharma Inc-Key Competitors 63

Kite Pharma Inc-Key Employees 64

Kite Pharma Inc-Locations And Subsidiaries 65

Head Office 65

Other Locations & Subsidiaries 65

Joint Venture 65

Recent Developments 66

Financial Announcements 66

Aug 08, 2017: Kite Reports Second Quarter 2017 Financial Results 66

May 08, 2017: Kite Reports First Quarter Financial Results 68

Feb 28, 2017: Kite Reports Fourth Quarter and Full Year 2016 Financial Results 70

Corporate Communications 72

Jul 09, 2018: Kite Names Michael Amoroso As Senior Vice President And Head Of Worldwide Commercial, Cell Therapy 72

Mar 16, 2017: Kite Announces Appointment of Renowned Cancer Researcher, Owen N. Witte, M.D., to its Board of Directors 73

Jan 05, 2017: Kite Pharma appoints new board member 74

Product News 75

07/20/2017: Kite Highlights Durable Complete Remissions Up to 56+ Months in Patients with Chemorefractory Aggressive Non-Hodgkin Lymphoma (NHL) after Anti-CD19 CAR T-Cell Therapy at the National Cancer Institute 75

06/12/2018: Clinical Data Highlighting Single-Cell Polyfunctionality as a Potential Predictor of Patient Response to CAR-T Cell Therapy Published in Blood 76

Apr 04, 2017: Kite Highlights Publication on Breakthrough in Generating Fully Functioning T Cells from Hematopoietic Precursor Cells by Leading Researchers at the University of California, Los Angeles 77

03/14/2017: Kite Pharma Highlights Publication from the National Cancer Institute Demonstrating Durable Complete Remissions in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma Following Low Dose Conditioning Chemotherapy and Anti-CD19 CAR T-Cell Therapy 78

Product Approvals 79

Jan 03, 2017: Kite Pharma Submits Investigational New Drug (IND) Application for KITE-718, an Investigational Next Generation T-Cell Receptor (TCR) Therapy Targeting Cancer Antigens MAGE A3 and MAGE A6 79

Other Significant Developments 80

Jan 11, 2018: Adimab Initiates Update on Clinical Progression of Partner Programs 80

Appendix 81

Methodology 81

About GlobalData 81

Contact Us 81

Disclaimer 81


List Of Figure

List of Figures

Kite Pharma Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Kite Pharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Kite Pharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Kite Pharma Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Kite Pharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7

Kite Pharma Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 8

Kite Pharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9

Kite Pharma Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10

Kite Pharma Inc, Medical Devices Deals, 2012 to YTD 2018 11


List Of Table

List of Tables

Kite Pharma Inc, Pharmaceuticals & Healthcare, Key Facts, 2016 2

Kite Pharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7

Kite Pharma Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8

Kite Pharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9

Kite Pharma Inc, Deals By Therapy Area, 2012 to YTD 2018 10

Kite Pharma Inc, Medical Devices Deals, 2012 to YTD 2018 11

Kite Pharma Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12

Kite Pharma Acquires Agensys Research Facilities from Astellas Pharma 15

Cell Design Labs Raises USD34.4 Million in Venture Financing 16

Kite Pharma Raises USD 20 Million In Series A Financing 17

Kite Pharma Raises USD 0.2 Million In Venture Financing 18

Kite Pharma Enters into Option Agreement with Netherlands Cancer Institute to License T Cell Receptor Cancer Immunotherapy Product Candidates 19

Kite Pharma and Gadeta Enter into Co-Development Agreement 20

Kite Pharma Enters into Partnership with Pfizer 21

Kite Pharma Forms Joint Venture with Fosun Pharma 22

Kite Pharma Enters into Agreement with Vitruvian Networks 23

Kite Pharma Enters into R&D Agreement with National Cancer Institute 24

Kite Pharma Enters into Agreement with Genentech 25

Kite Pharma Enters into Research Agreement with Leiden University Medical Center 26

Kite Pharma Enters into Research and Development Agreement with National Cancer Institute 27

Kite Pharma Enters into Research Agreement with GE Global Research 28

Kite Pharma Enters into Agreement with Leukemia & Lymphoma Society 29

Kite Pharma Enters into Co-Development Agreement with Bluebird bio 30

Adimab Enters into Research Agreement with Kite Pharma 31

Kite Pharma Extends Research Agreement with Tel Aviv Medical Center to Develop Novel Chimeric Antigen Receptor (CAR) 32

Kite Pharma Enters into Research Agreement with Tel Aviv Medical Center 33

Kite Pharma Amends R&D Agreement with National Cancer Institute for Cancer Immunotherapy Products 34

Kite Pharma to Enter into Licensing Agreement with Sangamo Therapeutics 35

Daiichi Sankyo Enters into Licensing Agreement with Kite Pharma 37

Kite Pharma Enters into Licensing Agreement with National Institutes of Health 38

Kite Pharma Enters into Licensing Agreement with National Institutes of Health 39

Kite Pharma Enters into Licensing Agreement with Regents of the University of California 40

Kite Pharma Enters into Licensing Agreement with Cell Design Labs 41

Kite Pharma Exercises Option for Licensing Agreement with Adimab 42

Kite Pharma Extends Licensing Agreement with Alpine Immune Sciences 43

Kite Pharma Enters into Licensing Agreement with National Institutes of Health 44

Amgen Enters into Licensing Agreement with Kite Pharma 46

Kite Pharma Enters into Licensing Agreement with National Institutes of Health for T Cell Receptor-Based Products 48

Kite Pharma Enters into Licensing Agreement with Cabaret Biotech 49

Kite Pharma Enters into Licensing Agreement with National Institutes of Health 50

Kite Pharma Raises USD409.7 Million in Public Offering of Shares 51

Kite Pharma Announces Exercise of Over-Allotment Option for Public Offering of Shares for USD37.5 Million 53

Kite Pharma Raises USD28.2 Million Underwriters Exercise of Over-Allotment Option of Public Offering of Shares 55

Kite Pharma Raises USD146.62 Million in IPO 57

Gilead Sciences and Kite Pharma Acquire Cell Design Labs 59

Gilead Sciences Acquires Kite Pharma for USD11.9 Billion 60

Kite Pharma Acquires T-Cell Factory 62

Kite Pharma Inc, Key Competitors 63

Kite Pharma Inc, Key Employees 64

Kite Pharma Inc, Subsidiaries 65

Kite Pharma Inc, Joint Venture 65

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

Kite Pharma Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.